Format

Send to

Choose Destination
Gastroenterol Hepatol. 2018 Jun - Jul;41(6):353-361. doi: 10.1016/j.gastrohep.2018.04.006. Epub 2018 May 11.

Resources used in the treatment of perianal Crohn's disease and the results in a real-life cohort.

[Article in English, Spanish]

Author information

1
Servicio de Aparato Digestivo, Hospital Universitario de La Princesa, Madrid, España. Electronic address: cristina.rubindecelix@salud.madrid.org.
2
Servicio de Aparato Digestivo, Hospital Universitario de Fuenlabrada, Madrid, España.
3
Servicio de Cirugía General y del Aparato Digestivo, Hospital Universitario de Fuenlabrada, Madrid, España.
4
Servicio de Radiodiagnóstico, Hospital Universitario de Fuenlabrada, Madrid, España.

Abstract

OBJECTIVE:

To study the multidisciplinary management of patients with Crohn's disease (CD) and perianal disease (perianal Crohn's disease, PCD), as well as to analyse a possible relationship between the recurrence of perianal symptoms, the type of fistula and the treatment used.

PATIENTS AND METHODS:

Descriptive, retrospective study of patients with PCD who were treated in the Inflammatory Bowel Disease Unit. Epidemiological, clinical, diagnostic and therapeutic variables were collected, as well as clinical outcome and response to treatment.

RESULTS:

Of the 300 patients who attended the outpatient clinic at a university hospital, 65 had PCD. Sixteen simple fistulas (24.6%) and 49 complex fistulas (75.4%) were diagnosed. The most commonly used diagnostic technique was the endoanal ultrasound (45%). Antibiotics were used in 77.4% of patients, and 70% needed anti-TNF therapy to manage the PCD. Surgery was performed on 75.4% of the patients overall. PCD recurred in 41.5% of cases, requiring a change of the biological drugs administered and/or surgery. Complex fistulas were more likely to require surgery (P=.012) and recurrence of PCD was also more common with complex fistulas (P=.036).

CONCLUSION:

Management of PCD must be multidisciplinary and combined. Most patients with complex PCD require treatment based on biological drugs. Despite therapy, remission of perianal symptoms is not achieved in a percentage of patients, supporting the need to develop new therapies for refractory cases.

KEYWORDS:

Anti-TNF; Biological drugs; Crohn's disease; Enfermedad de Crohn; Fármacos biológicos; Fístula perianal; Immunomodulators; Inmunomodulador; Perianal fistula

Supplemental Content

Full text links

Icon for Ediciones Doyma, S.L.
Loading ...
Support Center